181 related articles for article (PubMed ID: 21199794)
1. Lactate dehydrogenase B is critical for hyperactive mTOR-mediated tumorigenesis.
Zha X; Wang F; Wang Y; He S; Jing Y; Wu X; Zhang H
Cancer Res; 2011 Jan; 71(1):13-8. PubMed ID: 21199794
[TBL] [Abstract][Full Text] [Related]
2. NFκB up-regulation of glucose transporter 3 is essential for hyperactive mammalian target of rapamycin-induced aerobic glycolysis and tumor growth.
Zha X; Hu Z; Ji S; Jin F; Jiang K; Li C; Zhao P; Tu Z; Chen X; Di L; Zhou H; Zhang H
Cancer Lett; 2015 Apr; 359(1):97-106. PubMed ID: 25578782
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.
Oneyama C; Ikeda J; Okuzaki D; Suzuki K; Kanou T; Shintani Y; Morii E; Okumura M; Aozasa K; Okada M
Oncogene; 2011 Aug; 30(32):3489-501. PubMed ID: 21383697
[TBL] [Abstract][Full Text] [Related]
4. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.
Zhang H; Bajraszewski N; Wu E; Wang H; Moseman AP; Dabora SL; Griffin JD; Kwiatkowski DJ
J Clin Invest; 2007 Mar; 117(3):730-8. PubMed ID: 17290308
[TBL] [Abstract][Full Text] [Related]
5. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant.
Li T; Wang J; Wang X; Yang N; Chen SM; Tong LJ; Yang CH; Meng LH; Ding J
J Pharmacol Exp Ther; 2010 Sep; 334(3):830-8. PubMed ID: 20522531
[TBL] [Abstract][Full Text] [Related]
6. ATP-mediated protein kinase B Akt/mammalian target of rapamycin mTOR/p70 ribosomal S6 protein p70S6 kinase signaling pathway activation promotes improvement of locomotor function after spinal cord injury in rats.
Hu LY; Sun ZG; Wen YM; Cheng GZ; Wang SL; Zhao HB; Zhang XR
Neuroscience; 2010 Sep; 169(3):1046-62. PubMed ID: 20678995
[TBL] [Abstract][Full Text] [Related]
7. Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway.
Shibata T; Saito S; Kokubu A; Suzuki T; Yamamoto M; Hirohashi S
Cancer Res; 2010 Nov; 70(22):9095-105. PubMed ID: 21062981
[TBL] [Abstract][Full Text] [Related]
8. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
9. Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade.
Ma J; Meng Y; Kwiatkowski DJ; Chen X; Peng H; Sun Q; Zha X; Wang F; Wang Y; Jing Y; Zhang S; Chen R; Wang L; Wu E; Cai G; Malinowska-Kolodziej I; Liao Q; Liu Y; Zhao Y; Sun Q; Xu K; Dai J; Han J; Wu L; Zhao RC; Shen H; Zhang H
J Clin Invest; 2010 Jan; 120(1):103-14. PubMed ID: 20038814
[TBL] [Abstract][Full Text] [Related]
10. Involvement of the Akt/mTOR pathway on EGF-induced cell transformation.
Nomura M; He Z; Koyama I; Ma WY; Miyamoto K; Dong Z
Mol Carcinog; 2003 Sep; 38(1):25-32. PubMed ID: 12949840
[TBL] [Abstract][Full Text] [Related]
11. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth.
Sun Q; Chen X; Ma J; Peng H; Wang F; Zha X; Wang Y; Jing Y; Yang H; Chen R; Chang L; Zhang Y; Goto J; Onda H; Chen T; Wang MR; Lu Y; You H; Kwiatkowski D; Zhang H
Proc Natl Acad Sci U S A; 2011 Mar; 108(10):4129-34. PubMed ID: 21325052
[TBL] [Abstract][Full Text] [Related]
12. Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway.
Fang P; Hwa V; Rosenfeld RG
Exp Cell Res; 2006 May; 312(8):1229-39. PubMed ID: 16427044
[TBL] [Abstract][Full Text] [Related]
13. Brain-expressed X-linked 2 Is Pivotal for Hyperactive Mechanistic Target of Rapamycin (mTOR)-mediated Tumorigenesis.
Hu Z; Wang Y; Huang F; Chen R; Li C; Wang F; Goto J; Kwiatkowski DJ; Wdzieczak-Bakala J; Tu P; Liu J; Zha X; Zhang H
J Biol Chem; 2015 Oct; 290(42):25756-65. PubMed ID: 26296882
[TBL] [Abstract][Full Text] [Related]
14. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
15. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
[TBL] [Abstract][Full Text] [Related]
16. Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha.
Dan HC; Adli M; Baldwin AS
Cancer Res; 2007 Jul; 67(13):6263-9. PubMed ID: 17616684
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.
Sunayama J; Matsuda K; Sato A; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
Stem Cells; 2010 Nov; 28(11):1930-9. PubMed ID: 20857497
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth.
Liu X; Powlas J; Shi Y; Oleksijew AX; Shoemaker AR; De Jong R; Oltersdorf T; Giranda VL; Luo Y
Anticancer Res; 2004; 24(5A):2697-704. PubMed ID: 15517874
[TBL] [Abstract][Full Text] [Related]
19. Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway.
Chen W; Ma T; Shen XN; Xia XF; Xu GD; Bai XL; Liang TB
Cancer Res; 2012 Mar; 72(6):1363-72. PubMed ID: 22287548
[TBL] [Abstract][Full Text] [Related]
20. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
